Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNEUROPHARMACOLOGY

S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: II. Modulation of Hippocampal Serotonin Release in Relation to Potential Anxiolytic Properties

Mark J. Millan, Stephan Hjorth, Rosario Samanin, Rudy Schreiber, Robert Jaffard, Brigitte De Ladonchamps, Sylvie Veiga, Bertrand Goument, Jean-Louis Peglion, Michael Spedding and Mauricette Brocco
Journal of Pharmacology and Experimental Therapeutics July 1997, 282 (1) 148-161;
Mark J. Millan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Hjorth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosario Samanin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rudy Schreiber
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Jaffard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brigitte De Ladonchamps
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvie Veiga
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bertrand Goument
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Louis Peglion
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Spedding
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauricette Brocco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In these studies, we characterized the influence of the novel benzodioxopiperazine serotonin (5-HT)1A ligand, S 15535, on the release of 5-HT in rat hippocampus and compared its potential anxiolytic properties with those of the 5-HT1A receptor partial agonist, buspirone, the 5-HT1A antagonist, WAY 100,635 and the benzodiazepine, diazepam (DZM). (Doses are in milligrams per kilogram s.c., unless otherwise specified.) S 15535 dose-dependently (0.3–3.0) reduced dialysate concentrations of 5-HT in the hippocampus of anesthetized rats. This action of S 15535 (3.0) was blocked by WAY 100,635 (0.3), (−)-penbutolol (2.0) and (−)-tertatolol (8.0), antagonists at 5-HT1A autoreceptors. In rats, fear-induced ultrasonic vocalizations (USVs) were dose-dependently abolished by S 15535 (0.16–2.5 s.c. and 0.63–10.0 p.o.), an action mimicked by buspirone (0.02–2.5) and DZM (0.16–10.0). Further, the action of S 15535 (0.63) was abolished by WAY 100,635 (0.16) and (−)-penbutolol (10.0), which were inactive alone. S 15535 dose-dependently (0.63–10.0 s.c. and 2.5–40.0 p.o.) blocked aggressive encounters in isolated mice; buspirone (0.16–10.0) and, at high doses, DZM (2.5–40.0) were also effective. WAY 100,635 (0.16), which was inactive alone, fully antagonized the antiaggressive actions of S 15535 (2.5). In an elevated plus-maze, neither S 15535 (0.0025–10.0), buspirone (0.0025–10.0) nor WAY 100,635 (0.00063–0.63) significantly increased open-arm entries, whereas they were increased by DZM (0.16–0.63). In the pigeon conflict test, S 15535 (0.04–0.16 i.m.) markedly increased punished responses and only slightly decreased unpunished responses, even at a 64-fold higher dose. In contrast, buspirone (0.16–2.5 i.m.) and DZM (0.04–2.5 i.m.) showed no or a less marked (4-fold) separation between doses increasing punished and decreasing unpunished responses. In the presence of the 5-HT1A antagonist, (−)-alprenolol (10.0 mg/kg i.m.), S 15535 did not increase punished responses. In a Geller conflict paradigm in rats, S 15535 dose-dependently (0.3–3.0) increased punished responses, and its action (1.0) was blocked by (−)-penbutolol (8.0). S 15535 (0.63–40.0 s.c. and 2.5–40.0 p.o.) exerted little influence on motor behavior. In conclusion, in line with its net inhibition of serotoninergic transmission by activation of 5-HT1A autoreceptors and blockade of postsynaptic 5-HT1A receptors, S 15535 expresses anxiolytic activity. In addition, it displays antiaggressive (and antidepressant, accompanying paper) properties. Further, S 15535 does not compromise motor behavior at doses over which it expresses its anxiolytic properties. Thus, S 15535 represents a promising candidate for the treatment of anxious states in man.

Footnotes

  • Send reprint requests to: Dr. Mark J. Millan, Institut de Recherches Servier. Centre de Recherches de Croissy, Psychopharmacology Department. 125, Chemin de Ronde, 78290, Croissy-sur-Seine, Paris, France.

  • ↵1 Present address: Troponwerke, Institut for Neurobiology, Berliner Straáe 156, D-51063 Köln, Germany.

  • Abbreviations:
    AR
    adrenergic receptor
    BZP
    benzodiazepine
    DZM
    diazepam
    USV
    ultrasonic vocalization
    5-HT
    serotonin
    • Received March 19, 1996.
    • Accepted March 10, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 282, Issue 1
1 Jul 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: II. Modulation of Hippocampal Serotonin Release in Relation to Potential Anxiolytic Properties
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherNEUROPHARMACOLOGY

S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: II. Modulation of Hippocampal Serotonin Release in Relation to Potential Anxiolytic Properties

Mark J. Millan, Stephan Hjorth, Rosario Samanin, Rudy Schreiber, Robert Jaffard, Brigitte De Ladonchamps, Sylvie Veiga, Bertrand Goument, Jean-Louis Peglion, Michael Spedding and Mauricette Brocco
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 148-161;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherNEUROPHARMACOLOGY

S 15535, A Novel Benzodioxopiperazine Ligand of Serotonin (5-HT)1A Receptors: II. Modulation of Hippocampal Serotonin Release in Relation to Potential Anxiolytic Properties

Mark J. Millan, Stephan Hjorth, Rosario Samanin, Rudy Schreiber, Robert Jaffard, Brigitte De Ladonchamps, Sylvie Veiga, Bertrand Goument, Jean-Louis Peglion, Michael Spedding and Mauricette Brocco
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 148-161;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Substituted tryptamine activity at 5-HT receptors & SERT
  • In Vivo SRI-32743 Attenuates Tat Effects on Extracellular DA
  • Kv7 Opener Attenuates Seizures and Cognitive Deficit
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics